ReviewNPJ precision oncology2022

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

Emily J Lelliott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.